CNBX Pharmaceuticals Inc. is a clinical-stage company based in Bethesda, Maryland, focused on the discovery, development, and commercialization of novel cannabinoid-based products for cancer treatment. Its lead product, Cannabics SR, is an oral sustained-release capsule for cancer anorexia cachexia syndrome (CACS). Its second candidate, RCC-33, is a first-in-class anti-neoplastic drug for colorectal cancer. R&D is conducted in a government-licensed lab in Israel through its wholly owned subsidiary G.R.I.N Ultra Ltd.
Q2 FY2026 — expected 2026-07-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-12-01 | 2025-08-31 | 0001683168-25-008736 | EDGAR | 45K words |
| 2024-11-29 | 2024-08-31 | 0001683168-24-008433 | EDGAR | — |
| 2023-11-30 | 2023-08-31 | 0001683168-23-008557 | EDGAR | — |
| 2022-11-30 | 2022-08-31 | 0001683168-22-008095 | EDGAR | — |
| 2021-11-29 | 2021-08-31 | 0001683168-21-006005 | EDGAR | — |
| 2020-11-04 | 2020-08-31 | 0001683168-20-003686 | EDGAR | — |
| 2019-11-29 | 2019-08-31 | 0001683168-19-003852 | EDGAR | — |
| 2018-11-29 | 2018-08-31 | 0001683168-18-003584 | EDGAR | — |
| 2017-12-08 | 2017-08-31 | 0001683168-17-003260 | EDGAR | — |
| 2016-12-13 | 2016-08-31 | 0001683168-16-000925 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-01-14 | 2025-11-30 | 0001683168-26-000285 | EDGAR | 9K words |
| 2025-07-14 | 2025-05-31 | 0001683168-25-005075 | EDGAR | — |
| 2025-04-14 | 2025-02-28 | 0001683168-25-002511 | EDGAR | — |
| 2025-01-13 | 2024-11-30 | 0001683168-25-000267 | EDGAR | — |
| 2024-07-15 | 2024-05-31 | 0001683168-24-004831 | EDGAR | — |
| 2024-04-16 | 2024-02-29 | 0001683168-24-002440 | EDGAR | — |
| 2024-01-12 | 2023-11-30 | 0001683168-24-000255 | EDGAR | — |
| 2023-07-14 | 2023-05-31 | 0001683168-23-004890 | EDGAR | — |
| 2023-04-14 | 2023-02-28 | 0001683168-23-002379 | EDGAR | — |
| 2023-01-13 | 2022-11-30 | 0001683168-23-000174 | EDGAR | — |
| 2022-07-14 | 2022-05-31 | 0001683168-22-004948 | EDGAR | — |
| 2022-04-12 | 2022-02-28 | 0001683168-22-002526 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-17 | 0001683168-26-001883 | EDGAR | 1K words |
| 2025-01-30 | 0001683168-25-000583 | EDGAR | — |
| 2024-03-22 | 0001683168-24-001610 | EDGAR | — |
| 2023-02-08 | 0001683168-23-000628 | EDGAR | — |
| 2022-12-29 | 0001683168-22-008672 | EDGAR | — |
| 2022-07-25 | 0001683168-22-005100 | EDGAR | — |
| 2022-05-13 | 0001683168-22-003584 | EDGAR | — |
| 2022-03-28 | 0001683168-22-001999 | EDGAR | — |
| 2022-03-16 | 0001683168-22-001701 | EDGAR | — |
| 2022-02-17 | 0001683168-22-001084 | EDGAR | — |
175 total filings indexed. 143 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001343009 |
| Ticker | CNBX |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Headquarters | Bethesda, Maryland |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report